| Name | Title | Contact Details |
|---|
Dental Health Alliance is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2011, CareSync is the leading provider of software and services for chronic disease management, combining technology with 24/7 nursing services to facilitate care coordination among patients, family and caregivers and all providers. CareSync provides turnkey Chronic Care Management services as well as a software-only option, allowing practices of any size to easily meet the billing requirements for CPT code 99490. Additionally, CareSync`s certified technology makes it simple for providers to meet Meaningful Use 2 for Data Exchange, Messaging and Timely Access. CareSync patients are at the center of their healthcare, with access to health information, actionable goals, and Comprehensive Care Plan tasks. As a result, CareSync`s patients are experiencing more productive medical appointments and better health outcomes.
A premier provider of high quality, behavioral health care founded in 1999 and headquartered in central Pennsylvania, we operate over 80 facilities across the Commonwealth, New Jersey, and North Carolina and offer a full continuum of mental health, treatment and recovery services for adults and teens. Our dedicated admissions representatives are available to schedule confidential assessments and admissions, recommend appropriate treatment options, assist with insurance verification and facilitate complimentary transportation to and from our detox and inpatient program locations.
To Help Everyone Health and Wellness Centers is a non-profit organization that provides access to high quality healthcare and preventive education for underserved communities in Los Angeles.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.